Recently, small-molecule tropomyosin receptor kinase B (TrkB) agonist 7,8-dihydroxyflavone (DHF) has attracted substantial interest as a new possible option for management of traumatic brain injury [75]. This evidence concerns the gene NTRK2 and brain injury.